X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

Core Viewpoint - X4 Pharmaceuticals has announced a public offering of 45,860,000 shares of common stock priced at $2.90 per share, aiming to raise approximately $135 million to fund the development of its drug mavorixafor and for general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes pre-funded warrants for up to 700,000 shares at a price of $2.899 each, with an exercise price of $0.001 per share [1]. - The offering is expected to close on October 27, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 6,984,000 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund the pivotal Phase 3 development of mavorixafor for chronic neutropenic disorders, along with general administrative expenses, capital expenditures, and working capital [2]. Group 3: Company Background - X4 Pharmaceuticals focuses on developing therapies for rare hematology diseases, with mavorixafor being an orally available CXCR4 antagonist currently marketed in the U.S. as XOLREMDI® [5]. - The company is conducting a global Phase 3 clinical trial (4WARD) for mavorixafor in patients with chronic neutropenic disorders [5].